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The actin-bundling protein Fascin is
overexpressed in inflammatory bowel disease
and may be important in tissue repair
David Qualtrough*, Katie Smallwood, David Littlejohns, Massimo Pignatelli
Abstract
Background: Fascin is associated with increased cell motility in colorectal tumours but is absent from the normal
colonic epithelium. We examined the expression of fascin in inflammatory bowel disease (IBD) and its location at
regions undergoing restitution and regeneration. Tissue repair is essential for disease remission and we sought to
determine the effects of therapeutic modalities on fascin expression and function using an in vitro model.
Methods: Immunohistochemistry was performed on colonic tissue from IBD patients to determine changes in
fascin expression and distribution. A human colorectal epithelial cell line was treated with 5-aminosalicylate (a
common treatment for IBD), or sodium butyrate to determine the effect on fascin expression and cell motility.
Results: Fascin overexpression was observed in both ulcerative colitis and Crohn’s colitis and expression correlated
with disease severity. Immunoreactivity was more intense and widespread in Crohn’s compared to ulcerative colitis.
Interestingly, highly expressing foci were consistently observed at the edges of ulcers where flattened, motile
epithelial cells are actively involved in restitution, and also in areas of mucosal regeneration.
5-aminosalicylate reduced fascin expression in colorectal epithelial cells and inhibited their motility. Conversely,
sodium butyrate increased fascin expression and stimulated cell motility in the same cells.
Conclusions: Our data shows that fascin is overexpressed in inflammatory bowel disease and its location is
indicative of a role in tissue repair. Our in vitro studies show that different therapeutic modalities may have
converse effects on fascin expression and may have significant consequences for disease remission and the clinical
management of IBD.
Background
Ulcerative colitis (UC) and Crohn’s disease (CD) are
forms of inflammatory bowel disease (IBD) which affect
an estimated 1.4 million people in the USA and
2.2 million across Europe. UC exclusively affects the
large intestine, whereas CD affects the colon in 60% of
cases (known as Crohn’s colitis), but can also involve
other parts of the GI tract [1]. These common, chronic
and debilitating conditions remain incurable, with their
aetiology and pathogenesis not clearly understood.
Long-term illness greatly increases the risk of colorectal
cancer, which causes approximately 15% of all IBD
patient deaths [2]. The onset of cancer in IBD patients
is sudden, rapid, and highly aggressive, with a poor
prognosis. The occurrence of dysplasia in IBD is widely
accepted to be pre-malignant, but the likelihood of pro-
gression to cancer is difficult to predict [3]. Even the
distinction between low grade- and high-grade dysplasia
provides little indication of disease outcome [2] and
there is, therefore, an urgent need for biomarkers to
predict neoplasia in IBD.
Both UC and CD are characterised by mucosal infil-
tration of inflammatory cells and frequent epithelial
damage. This damage can result in destruction of the
mucosa and a breach in the barrier that this tissue pro-
vides against the luminal milieu. Complete remission of
IBD requires both a reduction in inflammation and
repair of the damaged epithelium. Inadequate or incom-
plete repair can result in the formation of a ‘leaky bar-
rier’ which can in turn perpetuate a vicious cycle of
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chronic inflammation [4]. The process of ‘healing’ areas
of the mucosa devastated by inflammation is widely
accepted to be a two-stage process comprising ‘restitu-
tion’ and ‘regeneration’ [5]. Restitution is characterised
by flattening and spreading of the epithelium at the
margins of the ulcer, with these cells migrating across
the denuded sub-mucosa to cover the damaged area.
Following restitution, the regeneration programme
requires widespread epithelial cell proliferation and for-
mation of characteristic glandular structures of the
intestinal crypts. Although several cytokines and growth
factors have been implicated in the restoration of
epithelium following injury, the cellular processes
underpinning this mechanism remain poorly understood
[5].
Current therapy for IBD, particularly UC, centres on
the long-term administration of the non-steroidal anti-
inflammatory drug (NSAID) 5-amino salicylate (5-ASA).
Shown to be effective in controlling intestinal inflamma-
tion in the majority of patients, 5-ASA also reduces col-
orectal cancer risk in patients with IBD [6,7].
Other workers in the field have proposed sodium
butyrate, a fermentation product of dietary fibre, as a
potential therapy for IBD. Trials using butyrate irriga-
tion led to symptomatic amelioration in UC patients
[8,9]. Luminal levels of butyrate may be modulated
through the dietary intake of fibre and are found in the
millimolar range [10].
Among the most pressing current issues in the clinical
management of IBD are a need to further our under-
standing of intestinal wound healing and to understand
the effects of therapeutic modalities on tissue repair as
this is crucial for disease remission.
Fascin (fascin-1) is a 55kDa actin-bundling protein
which localises to the core actin bundles of spikes and
filopodia at the leading edge of migratory cells. It is
known to be overexpressed in various cancers and has
been shown to increase motility in cells from several dif-
ferent tissues [11]. Work in this laboratory has shown
fascin to be completely absent from the normal colorec-
tal epithelium but widespread in colorectal tumours
[11,12]. Fascin expression has been shown to correlate
with an increased risk of malignant progression and
with a poorer disease prognosis making it a potential
biomarker in colorectal neoplasia [12,13].
As yet, there are no published reports of fascin expres-
sion in IBD, but it is our hypothesis that fascin will be
involved in tissue repair in IBD. The changes in motile
behaviour demonstrated by tumour cells mimic those
occurring during tissue repair and require dynamic rear-
rangements in the actin cytoskeleton, governed by actin-
binding proteins such as fascin.
The first aim of this study was to determine the
expression of fascin in clinical samples of IBD with
particular attention to areas of restitution and regenera-
tion. Samples of resection margins from patients under-
going surgery for diverticulitis were included as these
show low-grade mucosal inflammatory infiltration.
Secondly, in order to elucidate the potential modula-
tion of fascin by therapeutic intervention and the subse-
quent consequences for epithelial repair, we studied the
effects of 5-ASA and sodium butyrate on fascin expres-
sion and cell motility using an in vitro cell line model.
We now show, for the first time, that fascin is overex-
pressed in IBD and expression is associated with regions
of active mucosal repair. Furthermore, therapeutic mod-




Ethical approval was obtained from the North Somerset &
South Bristol Research Ethics Committee (REC reference
04/Q2003/49). All tissue samples were obtained from the
files of the Department of Histopathology, Bristol Royal
Infirmary. These samples were anonymised by a third
party and the investigators had no access to patient
information.
Immunohistochemistry
A total of 41 surgical specimens of resected colorectal
tissue from IBD patients were immunohistochemically
stained for fascin as described previously [11,12]. We
also examined samples of normal colorectal mucosa and
11 samples of resection margins from patients under-
going surgery for diverticulitis as these display low grade
mucosal inflammation.
Fascin was detected using a mouse monoclonal anti-
body (Dako-Cytomation, Glostrup, Denmark) as pre-
viously described [11,12]. Negative controls had no
primary antibody applied.
Stained samples were scored by two independent
observers in terms of the proportion of epithelial cells
staining positive (1 for <20%, 2 for >20%) and also the
intensity of epithelial staining relative to that observed
in adjacent endothelial cells (0,1,2 for negative, weak,
moderate/strong, respectively) which act as an internal
positive control [11,12]. From the anonymised histology
reports, disease activity was scored 0, 1, or 2 for quies-
cent, low/moderate, or severe activity, respectively.
Statistical analysis
The immunohistochemistry scores were analysed for
specific correlations using Kendall’s tau B analysis as
previously described [12]. Correlations were checked
between proportion and intensity of fascin immunoreac-
tivity, disease activity, and the presence of dysplasia.
These analyses yield a value between zero and one (one
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being the strongest possible correlation and zero indi-
cating no correlation at all) and a p-value to indicate
the significance of the correlation. A p-value of less than
0.05 is considered statistically significant (*, p = < 0.05;
**, p = < 0.01; ***, p = < 0.001).
Cell Lines and treatments
The HT29 cell line was originally derived from a spora-
dic colonic adenocarcinoma and was maintained in cul-
ture in DMEM supplemented with 10% FBS [14].
For treatments, 1 × 106 cells were seeded per 25 cm2
culture flask in triplicate for each dose and control, and
the cells allowed to recover for 48 hours prior to treat-
ment. 5-ASA (Sigma) was dissolved in DMEM supple-
mented with 2% FBS to produce a 50 mM solution and
the pH adjusted to 7.4. This stock solution was diluted
further in DMEM (2% FBS) for cell treatments. The
5-ASA was made up fresh immediately prior to each
experiment and protected from light throughout the
procedure. Sodium butyrate (Sigma) treatments were
carried out as described previously [15]. Apoptosis was
assessed as previously described [15]. The level of apop-
tosis in cultured colon cells can be assessed by measur-
ing the proportion of cells that detach from the flask
and float in the medium [15 and references therein]
Apoptosis was confirmed in these floating cells by mor-
phology (following acridine orange staining). Acridine
orange staining was performed as previously described
with at least 300 cells scored for each sample. The pro-
portion of cells exhibiting apoptotic morphology was
>90% in the floating cell population, and this proportion
remained constant following treatment. Therefore, the
proportion of cells floating in the medium can be used
as a measure of the extent of apoptosis in the culture.
Western blotting analysis was performed on attached
cells-thereby precluding apoptotic cells from this mea-
sure of fascin expression.
Western Blot Analysis
Cell lysates of 2 × 106 cells were prepared for western
blotting as described previously [16]. A mouse monoclo-
nal antibody raised against fascin was obtained from
Dako (Dako-Cytomation, Carpinteria, CA). Blots were
subsequently probed with anti a-tubulin (Sigma, UK) to
show equal sample loading.
Cell motility assays
Cell migration assays were carried out using a transwell
filter migration assay as previously described [12]. The
lower chamber was filled with Calcium Free-DMEM
supplemented with 5% FBS to act as an attractant. Fol-
lowing a 24 hour incubation and staining with haemo-
toxylin, cells on the lower filter surface were considered
migratory and counted in 10 fields at ×20 magnification.
Results
Fascin expression is expressed in inflamed colonic
epithelium
Previous studies have shown that fascin is not expressed
in the epithelial cells of the normal colonic mucosa, but
is broadly expressed in the endothelial cells, fibroblasts
and infiltrating lymphocytes of the lamina propria and
submucosa [11,12]. Our previous study of colorectal
adenomas showed epithelial fascin expression focussed
around the tumour stalk, provoking the hypothesis that
fascin expression may be modulated by inflammatory
mediators [12]. In order to test this hypothesis immuno-
histochemistry was first performed on 11 tissue samples
of resection margins from patients undergoing surgery
for diverticulitis as these samples show low level inflam-
mation. In 10 out of the 11, epithelial fascin immunor-
eactivity was focally observed in epithelial cells at the
very base of the colonic crypts (Figure 1A). This obser-
vation is the first time that fascin expression has been
observed in non-neoplastic colorectal epithelium and led
us to question the relationship between fascin and
inflammatory conditions of the colon.
Fascin is overexpressed in inflammatory bowel disease
showing stronger and more widespread expression in
Crohn’s compared with ulcerative colitis
Having shown that epithelial fascin expression was
observed in the presence of low-level colonic inflamma-
tion, fascin immunohistochemistry was performed on 41
samples of resected colorectal mucosa from patients suf-
fering from IBD. Fascin was widely overexpressed in the
epithelium of IBD-involved tissue and representative
results are shown in Figure 1. The data from the subse-
quent scoring of these samples is summarised in Figure 2.
Strong fascin staining was frequently observed toward the
crypt bases in the elongated crypts associated with
IBD (Figure 1B and 1C) but also showed a more patchy
distribution throughout the glands (Figure 1D).
Strikingly, following scoring of the immunostaining, it
was found that both the proportion of positive epithelial
cells and the intensity of fascin staining (relative to
internal positive control) was significantly greater in
samples of Crohn’s compared with UC (Figure 2). Stain-
ing intensity also positively correlated with disease activ-
ity (as determined by the consulting pathologist) for
both conditions (Tau B = 0.223, p = <0.05). The inten-
sity of fascin stain observed in the sample was also
found to correlate with the proportion of fascin-positive
epithelium (Tau B = 0.621, p = < 0.001).
Previous study has shown that fascin is overexpressed
in both the benign and malignant stages of colorectal
neoplasia and is associated with malignant progression
of these tumours [11,12]. Increased risk of colorectal
cancer is an important clinical consideration in IBD,
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Figure 1 Fascin is overexpressed in inflammatory bowel disease and in colonic epithelium actively undergoing restitution and
regeneration. Fascin immunoreactivity was detected in specimens of human colorectal mucosa by immunoperoxidase staining. A: Diverticulitis
resection margin showing positive staining in the crypt base - 200 × magnification. B: Ulcerative colitis showing positive staining in the base of
the elongated crypts - 100 ×. C: Crohn’s colitis showing strong positive staining toward the base of the elongated crypts - 100 ×. D: Crohn’s
colitis showing patchy fascin immunoreactivity throughout the gland - 200 ×. E: Ulcerative colitis with low-grade dysplasia showing strong and
widespread fascin expression - 100 ×. F: Ulcerative colitis with high-grade dysplasia showing strong and widespread fascin expression - 200 ×. G:
Ulcerative colitis showing fascin staining in the flattened epithelial cells undertaking restitution - 200 ×. H: enlargement of an area of panel G
illustrating the fascin-positive epithelial cells (arrowheads). I: fascin positive epithelial cells undertaking restitution in a sample of Crohn’s colitis. J:
A regenerative polyp in a sample of ulcerative colitis showing fascin positivity in the newly forming crypts - 200 ×. K & L: Fascin expression in
branching crypts (arrowheads) in regenerating ulcerative colitis tissue - 200 ×.
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and malignant progression of areas of dysplasia remains
highly unpredictable [2]. In this study, strong fascin
expression was observed in IBD samples showing either
low or high grade dysplasia (Figure 1E), or cancer. Both
the intensity of epithelial fascin immunoreactivity (Tau
B = 0.391, p = <0.05) and the proportion (Tau B =
0.406, p = < 0.01) of positive epithelial cells in the tissue
significantly correlated with the presence of areas of
dysplastic epithelium.
Fascin is overexpressed in colonic epithelium actively
undergoing restitution and regeneration
Inflammatory infiltration in IBD frequently results in
complete destruction of the mucosal layer resulting in
areas of ulceration. Repair of these gaps in the epithelial
barrier occurs as a two-stage process, termed restitution
and regeneration [5]. In the sample group used, all of
the 11 sections showing signs of active restitution
stained positive for fascin in the flattened epithelial cells
moving to cover the denuded area (Figure 1G, H).
Fascin staining was also observed in the newly formed
immature crypts of regenerative polyps (Figure 1J) and
in epithelial glands undergoing crypt fission - a relatively
common observation in IBD tissue undertaking regen-
eration (Figure 1K). Taken together, these data suggest
that fascin could play an important role in IBD and
could be vital for disease remission through modulating
mucosal repair.
5-aminosalicylate reduces fascin expression and cell
motility whereas sodium butyrate has a converse effect
We have established above that fascin is overexpressed
in IBD, and that expression is associated with areas
undertaking repair. As fascin is known to promote cell
motility in neoplastic colorectal epithelial cells [12], and
motility is a key factor in epithelial restitution, we aimed
to determine the effect of therapeutic modalities used in
the treatment of IBD on fascin expression and cell moti-
lity in vitro.
5-aminosalicylate (5-ASA) is widely used in the clini-
cal management of IBD, whereas the short chain fatty
acid sodium butyrate, a luminal fermentation product
of dietary fibre, has been proposed for use in IBD
treatment [6,9].
In order to determine the effect of 5-ASA or butyrate
on fascin expression we treated HT29 colorectal epithe-
lial cells with a range of doses. Following 48 hours of
treatment, the cells were counted and samples prepared
in order to assay fascin expression by western blotting
(Figure 3A). Both 5-ASA and butyrate reduced attached
cell yield and induced apoptosis in the HT29 cells as
described previously [15]. Apoptotic cells were not
included in the analysis of fascin expression.
5-ASA treatment caused a decrease in fascin expres-
sion compared with control, whereas butyrate strongly
enhanced fascin expression in a dose-dependent manner
(Figure 3A). Promoter reporter assays using the full
length fascin promoter [17] showed that regulation
occurred, in both cases, at the transcriptional level (data
not shown).
In order to determine whether 5-ASA and butyrate
affect cell motility in this in vitro model, cells were
seeded on collagen-coated transwell filters as previously
described [12] and simultaneously treated with either
5-ASA or butyrate at doses which were shown not to
significantly induce apoptosis (10 mM and 1 mM,
Figure 2 Fascin expression is stronger and more widespread in Crohn’s colitis compared with Ulcerative colitis. A graphical summary of
the immunohistochemical study of fascin expression in IBD. Samples were scored high or low for the proportion of epithelium staining positive
(low = <20%; high = >20%), and the intensity of the epithelial fascin immunoreactivity. The graphs illustrate a significant increase in both the
proportion (Ttest p = 0.0017) and intensity (Ttest p = 0.0013) of fascin immunoreactivity in Crohn’s compared with ulcerative colitis samples.
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Figure 3 5-aminosalicylate reduces fascin expression and cell motility in colorectal epithelial cells, whereas sodium butyrate has a
converse effect. A: HT29 cells were treated with a range of doses of either 5-ASA or butyrate as indicated. Attached cell yields and percentage
of apoptotic cells were determined and these data represent the mean of three independent experiments performed in triplicate ±SEM. Also
shown are the subsequent western blot analyses of fascin expression. These blots are representative of three independent experiments and were
re-probed for a-tubulin to show even sample loading. SW480 lysate was included as a positive control having been shown previously to express
relatively high levels of fascin [Qualtrough et al., 2009]. B: The effect of 10 mM 5-ASA or 1 mM butyrate treatment on cell motility was
determined on HT29 cells as measured by Boyden chamber assay using 5%FBS as an attractant (**, p = <0.01; ***, p = <0.001). Three
independent experiments were carried out in triplicate and the data are expressed as the mean ± S.E.M.
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respectively-Figure 3A). Motile cells were counted 24
hours later (Figure 3B). 5-ASA significantly reduced cell
motility in HT29 cells whereas, conversely, butyrate
stimulated cell migration.
Discussion
We show here, for the first time, that the actin bundling
protein fascin is overexpressed in IBD, and may play an
important role in tissue repair following inflammatory
damage. Our in vitro findings suggest that therapeutic
approaches for IBD could influence fascin expression,
subsequently producing unwanted side-effects on tissue
repair and thereby influencing achievement of remission.
We have shown previously that fascin is absent from the
normal colorectal epithelium but overexpressed in both
benign and malignant tumours where it is associated with
enhanced cell motility [11,12]. Our previous findings in
colorectal adenomas, where the tumour stalk frequently
showed the strongest fascin immunoreactivity, suggest fas-
cin regulation occurs through epithelial-mesenchymal
crosstalk, potentially through inflammatory mediators
[12]. This notion of inflammatory induction of fascin
expression in the epithelium is supported here by the
widespread expression of fascin in tissue resected from
patients with IBD. A positive correlation was observed
between the disease activity recorded by the pathologist
and the intensity of fascin immunoreactivity further sup-
porting the idea of an inflammation-mediated regulation
of fascin expression. Also in keeping with these results is
the observation of epithelial fascin expression at the crypt
base in tissue from patients undergoing surgery for diverti-
culitis, which display low-grade inflammation.
The increased proportion and intensity of fascin stain-
ing observed in samples of Crohn’s compared with UC
raises questions about the fundamental difference
between these classifications of IBD. As it was only the
epithelial immunoreactivity that was scored, this differ-
ence cannot be attributed to the ability of Crohn’s colitis
to affect deeper layers of the bowel wall than UC, but
rather resides in the mechanism of fascin regulation.
IBD carries an increased risk of colorectal cancer,
resulting in the deaths of 15% of IBD patients [2].
Malignant progression is highly unpredictable and there-
fore the identification of prognostic biomarkers of
tumourigenic potential is of key importance [2]. In this
study we showed that both the proportion and intensity
of epithelial fascin stain significantly correlated with the
presence of dysplasia or cancer. Further study, of a lar-
ger sample group with long-term clinical follow-up, will
be necessary to confirm the validity of fascin as a bio-
marker for tumorigenesis in IBD. The role of fascin in
the malignant progression of sporadic colorectal
tumours [12] does suggest that fascin merits further
investigation in the neoplastic transformation of IBD.
One of the most intriguing observations in our study
of fascin expression in IBD was the focal expression of
fascin in regions demonstrating active tissue repair. Fas-
cin expression was found in all areas of restitution
observed, and also in regenerative polyps and branching
crypts, suggesting a role throughout the various stages
of the repair process. Our previous work has shown that
fascin can promote motility in benign, as well as malig-
nant colorectal epithelial cells [12], and it would have
been reasonable to hypothesise that fascin would be
expressed in the motile cells undertaking restitution.
Furthermore, fascin has been shown to modulate cell
adhesion and could therefore also function in the
dynamic adhesive changes required for both restitution
and crypt fission [11]. These data suggest that regulation
of fascin could be important in achieving and maintain-
ing remission in patients with IBD.
One of the most broadly used treatments for the
maintenance of remission in IBD is 5-ASA and previous
work has shown this drug to induce apoptosis in HT29
cells in a dose-dependent manner [18]. We show here
for the first time that treatment of the colorectal epithe-
lial cell line HT29 with this drug led to a decrease in
fascin expression and a retardation of cellular motility.
Long term use of 5-ASA in patients with IBD is
known to reduce cancer risk [19,20]. We postulate
based on our findings here that this chemopreventive
effect may, in part, be explained by the down regulation
of fascin expression-with fascin being known to be
involved in malignant progression of the colorectal
epithelium [12]. This repression of cellular motility
represents a key anti-cancer effect of 5-ASA treatment.
Conversely, considering the potential role of fascin in
tissue repair, this would suggest that 5-ASA could hin-
der wound repair and thus impede remission in patients
with active disease. The published evidence is somewhat
conflicting as there are reports to suggest that NSAIDs
can both impair wound healing [21] and that 5-ASA can
promote intestinal repair [22]. However, the possibility
exists that 5-ASA could have some detrimental effects
in IBD patients in addition to its obvious benefits. This
paradox in the effect of 5-ASA, and also the role of fas-
cin, could have important consequences for the clinical
management of IBD. To this end, our findings suggest
that increased luminal levels of butyrate could comple-
ment 5-ASA in promoting remission whilst maintaining
potent chemopreventive effects against tumorigenesis.
Previous work has suggested that sodium butyrate
could have beneficial effects for IBD sufferers [8,9]. This
fermentation product of dietary fibre is known to be
present in the colonic lumen in the millimolar range
and levels can be modulated by intake of suitable dietary
substrate [10]. We, and others, have previously shown
that butyrate has potent chemopreventive effects against
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colorectal tumorigenesis through the modulation of dif-
ferentiation and apoptosis in colorectal epithelial cells
[15,23,24].
We show here that butyrate upregulates fascin expres-
sion and significantly stimulates colorectal epithelial cell
motility. These data suggest that butyrate will aid colo-
nic tissue repair and therefore speed remission in IBD.
This short chain fatty acid has already been proposed to
promote wound healing in the small intestine [25].
Although our data suggest that fascin may be involved
in tumorigenesis, butyrate has been shown to elicit
potent anti-tumour effects. We propose that the combi-
natorial use of butyrate, or dietary modulation of its
levels, could favourably complement 5-ASA use in the
clinical management of IBD.
Conclusions
We have shown for the first time that fascin is impor-
tant in the pathogenesis and remission of IBD and could
have important implications for its clinical management
as fascin can potentially be manipulated using existing
therapeutic approaches and modulation of diet.
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